Award. Synthesis and bioanalytical analysis of small molecules for the ncats early translational branch chemistry program
Ended Purchase Order Awarded
- Contract number
- 75N95025P00412
- Awardee
-
Chemogenics Biopharma, LLC UEI MQLWQEJKQLR3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $101,000
Award facts
- Opportunity
-
- Synthesis of HNMT, NNMT intermediates and PK Pre-Solicitation · 75N95025Q00236 · Posted Aug 12, 2025
- Contract value 100% obligated
- $101,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27713, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute on Drug Abuse awarded a $101,000 firm fixed-price purchase order to Chemogenics Biopharma, LLC on September 16, 2025, for synthesis and bioanalytical analysis services supporting the National Center for Advancing Translational Sciences (NCATS) Early Translational Branch Chemistry Program. The contract, which extends through July 15, 2026, is performable in Durham, North Carolina. This procurement does not utilize a small business set-aside designation. The work involves custom synthesis of small molecule inhibitors targeting physiological methyltransferases implicated in disease, including delivery of 100 grams each of two specified chemical compounds with greater than 95% purity and optical purity exceeding 98%, accompanied by comprehensive spectroscopic characterization and analytical data.
In addition to chemical synthesis, the contract encompasses pharmacokinetic analysis of small molecule compounds using mouse models across multiple routes of administration and tissue types to generate exposure data supporting compound selection for proof-of-concept studies. Chemogenics Biopharma was selected as the sole-source contractor based on its demonstrated prior performance on similar NCATS projects. The company, registered in the System for Award Management since April 2011, specializes in custom chemical synthesis and bioanalytical services for pharmaceutical and medical research institutions, with previous federal contract experience totaling approximately $513,040 across multiple NIH agencies.
Quick answers
Who was awarded contract 75N95025P00412?
75N95025P00412 was awarded to Chemogenics Biopharma, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 16, 2025.
How much is contract 75N95025P00412 worth?
The government has obligated $101,000 on 75N95025P00412.
Was contract 75N95025P00412 competed?
The extent of competition for 75N95025P00412 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award